Leucine-rich single-pass membrane protein 1 (LSMEM1)

Leucine-rich single-pass membrane protein 1 (LSMEM1) is a small integral membrane protein encoded by the LSMEM1 gene on chromosome 7q31.1 in humans[2][6][12]. The protein consists of 131–133 amino acids, contains a single transmembrane domain, and has a molecular weight of approximately 14.2–14.5 kDa[2][4][5]. LSMEM1 is highly expressed in skeletal muscle, as well as in nerve tissue, and displays moderate expression in several other tissues[2]. It is associated with cellular processes such as injury, inflammation, and especially the regulation of lipid metabolism, and it plays a critical role in the delayed progression of chronic kidney disease (CKD) by controlling lipid droplet accumulation in proximal tubular epithelial cells[1]. While direct evidence as a therapeutic target is currently lacking, its functional role in CKD pathophysiology and clinical associations with Parkinson’s disease (as a biomarker) suggest potential clinical importance[1][2]. LSMEM1 commonly interacts with other integral membrane proteins (such as MAL, APP, and LSMEM2), but no small molecule or biologic therapeutics are currently known to target it[2]. There are no widespread safety concerns or established therapeutic challenges reported for LSMEM1 to date.

Other names

C7orf53FLJ39575chromosome 7 open reading frame 53leucine-rich single-pass membrane protein 1LSMEM1